Chemo combo (nanoliposomal irinotecan, oxaliplatin, capecitabine) before surgery for locally advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your cancer is a type called MSS/pMMR adenocarcinoma (not MSI-H/dMMR).
- The cancer is locally advanced in the colon or upper rectum and cannot be treated with radiation.
- You have not had any previous chemotherapy, radiation, or surgery for this cancer.
- You are able to take oral medications and have adequate organ function (kidneys, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
This trial tests a combination of drugs before surgery for locally advanced colorectal cancer. The goal is to see if this treatment shrinks the tumor and improves surgical outcomes.
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a combination of chemotherapy (CapeOX), a targeted drug (bevacizumab), and an immunotherapy (anti-PD1) given before surgery for colorectal cancer that has come back locally (in the same area). The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.